(212) 861-9797
Book an Appointment
(212) 861-9797
Book an Appointment
Google Reviews
The most highly trained and awarded eye doctors in the world are in your neighborhood, with offices conveniently located in Manhattan, Brooklyn, and Westchester.
Book Now
Of Combined Eye Surgery Experience
Eye Procedures Completed
Lectures Nationally & Internationally
From the moment you enter the office you are treated with respect from all the staff. The office operates efficiently to ensure that all patients have the time to be seen and talk with their physicians. I am very pleased with the care. Compassion and overall kindness that has been shown to me.
I have been seeing Dr. Engelbert for several years. He is smart, compassionate, and skilled. He has maintained the quality of my vision, and I consider myself extremely lucky to have been referred to him for my care.I recommend him without reservation.
The service level is excellent. Professional and courteous. Dr. Cooney is one of the most knowledgeable and friendliest doctors I ever had. I wish all doctors could follow his example. He is a great listener and pays close attention to detail. I recommend him highly.
Our internationally-renowned ophthalmologists and SYFOVRE™ Pegcetacoplan Injection specialists have trained and taught at some of the finest and most respected academic institutions in the world. As leading eye doctors and the best-rated SYFOVRE™ Pegcetacoplan Injection specialists, they have devoted their time and resources to research and the development of new diagnostic and therapeutic strategies. This exceptional and unique expertise, joined with their attentive, empathetic concern and careful approach means that even expert ophthalmologists turn to VRMNY doctors first when they or their families need care.
SYFOVRE™ is a novel drug from Apellis Pharmaceuticals which recently received FDA-approval following clinical trials showing its ability to slow the progression of retinal damage due to “geographic atrophy” caused by advanced dry Age-Related Macular Degeneration (AMD).
AMD is the most common cause of vision loss in people over 50. It is estimated that more than 8 million people in the US have some form of this eye disease.
Injections of SYFOVRE™ administered monthly or once-every-other-month showed a clinically meaningful reduction in growth of geographic atrophy, and this effect increased over time. The drug works by inhibiting parts of the body’s inflammatory response that contribute to geographic atrophy.
SYFOVRE™ is delivered by injection into the eye, like drugs used to treat other retinal diseases including wet AMD and macular edema due to diabetic retinopathy or retinal vein occlusion.
The approval of SYFOVRE™ is a significant step forward for people living with AMD, as this is the first time a drug has been FDA-approved for treating vison loss related to the dry form of AMD. However, while SYFOVRE™ may help slow vision loss in treated patients, it does not stop or reverse the course of the disease. Like the other injectable drugs used in the retinal field, there are risks associated with injection, mainly infection or intraocular inflammation.
VRMNY takes pride in offering our patients the most advanced treatment options for their retina condition. The newly approved SYFOVRE™ drug is another tool in our armamentarium.